Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors

被引：0
|
作者：
Li, Jin
Cao, Junning
Wang, Jin
Li, Baoyue
Chi, Haidong
Gao, Ling
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT158
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
    Junning Cao
    Jian Zhang
    Wei Peng
    Zhiyu Chen
    Songhua Fan
    Weiguo Su
    Ke Li
    Jin Li
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 259 - 269
  • [32] IMC-18F1, a recombinant human monoclonal antibody (MAb) against the vascular endothelial growth factor receptor-1 (VEGFR-1), in the treatment of patients (pts) with advanced solid malignancies: A Phase 1 study
    Krishnamurthi, S.
    Goncalves, P. H. B.
    Fox, F.
    Hall, N.
    Rowinsky, E.
    Schwartz, J.
    Youssoufian, H.
    LoRusso, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 127 - 128
  • [33] A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
    E. Gabriela Chiorean
    Christopher Sweeney
    Hagop Youssoufian
    Amy Qin
    Aruna Dontabhaktuni
    Nick Loizos
    Johannes Nippgen
    Robert Amato
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 595 - 604
  • [34] A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
    Chiorean, E. Gabriela
    Sweeney, Christopher
    Youssoufian, Hagop
    Qin, Amy
    Dontabhaktuni, Aruna
    Loizos, Nick
    Nippgen, Johannes
    Amato, Robert
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 595 - 604
  • [35] A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors
    Kurzrock, Razelle
    Patnaik, Amita
    Aisner, Joseph
    Warren, Terri
    Leong, Stephen
    Benjamin, Robert
    Eckhardt, S. Gail
    Eid, Joseph E.
    Greig, Gerard
    Habben, Kai
    McCarthy, Cinara D.
    Gore, Lia
    CLINICAL CANCER RESEARCH, 2010, 16 (08) : 2458 - 2465
  • [36] Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors
    Rothenberg, Mace L.
    Poplin, Elizabeth
    Sandler, Alan B.
    Rubin, Eric H.
    Fox, F.
    Schwartz, J.
    Vermeulen, Wendy
    Youssoufian, Hagop
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3553S - 3554S
  • [37] Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies
    Chiorean, E.
    Sweeney, C.
    Youssoufian, H.
    Fox, F.
    Katz, T.
    Rowinsky, E.
    Amato, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 162 - 162
  • [38] A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
    Wang, Fen
    Molina, Julian
    Satele, Daniel
    Yin, Jun
    Lim, Vun-Sin
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 658 - 665
  • [39] A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
    Fen Wang
    Julian Molina
    Daniel Satele
    Jun Yin
    Vun-Sin Lim
    Alex A. Adjei
    Investigational New Drugs, 2019, 37 : 658 - 665
  • [40] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors
    Cao, Junning
    Zhang, Jian
    Peng, Wei
    Chen, Zhiyu
    Fan, Songhua
    Su, Weiguo
    Li, Ke
    Li, Jin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 259 - 269
12345